Cornea

Grace Walther, first author of the study, described that lens centration on the eye may be beneficial for improving vision. Association for Research in Vision and Ophthalmology annual meeting.

John D. Gelles, OD, and Steven A. Greenstein, MD, share some insights into the new data on corneal cross-linking presented at IKA Keratoconus Symposium.

At the IKA Keratoconus Symposium, Justin Schweitzer, OD, FAAO, presented on establishing the keratoconus diagnosis alongside Kourtney Houser, MD.

President and CEO of the International Keratoconus Academy Andrew Morgenstern, OD, FAAO, FNAP, shares some snippets about the live white paper development session and the patient Q&A happening at the inaugural IKA Keratoconus Symposium.

Uri Soiberman, MD, shares some key takeaways from his presentation at the inaugural IKA Keratoconus Symposium.

The endothelial cells play an essential role in vision. They ensure that the cornea remains transparent by keeping it partially dehydrated.

Procedure provides ophthalmologists with another treatment option.

According to the company, KPI-012 could become the first approved treatment for persistent corneal epithelial defect across all its various etiologies.

Ophthalmologists can learn the latest techniques to help patients like Tommy Pham from the New York Mets during the first annual IKA Keratoconus Symposium: Front to Back and Everything In Between, taking place April 22-23 in Scottsdale, Arizona.

Cochair Elizabeth Yeu, MD, highlights what this program will mean for ophthalmologists, optometrists, and their patients.

Alcohol abuse is associated with significant alterations to corneal endothelial density and morphology.

The month will serve to educate the public on a variety of women’s vision issues.

Ehsan Sadri, MD, FACS, and William Trattler, MD, highlight some of the pending FDA approvals and PDUFA dates in the anterior segment sector and what these products will mean for ophthalmologists and their patients.

According to researchers, using nanoparticles to encapsulate eye medication decreased graft rejection while requiring fewer and smaller doses.

Physicians making sense of the cornea transplant alphabet soup.

Medical student’s vision was threatened by keratoconus, and early diagnosis and treatment could prove to be key to preserving the patient’s vision.

Kamran M. Riaz, MD, a clinical associate professor and director of Medical Student Research at the Dean A. McGee Institute at the University of Oklahoma, recently discussed with Ophthalmology Times some of the latest trends in cornea treatment.

According to James Chodosh MD, MPH, some corneal conditions may not be treatable with a transplant.

Eye care providers must look beyond visual acuity in screening for disease.

The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.

Corneal neurotization is an efficacious procedure to restore sensation to a neurotrophic cornea, involving the surgical transfer of sensory nerve fibers to the cornea.

CEO and cofounder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, sits down to discuss the inaugural symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.

Over the years, IKA has become an invaluable resource for eye care professionals.

After comparing two techniques of corneal transplant tissue preparation, research shows a newer, faster technique is safe and effective.

Stephen Pflugfelder, MD, professor and director of the Ocular Surface Center at Baylor College of Medicine in Houston, Texas, presents a challenging diagnostic dilemma.

CXL has been proven effective to treat patients with corneal ectasias.

Receiving FDA orphan drug designation allows the company to proceed with plans to advance the development of BRM424, a novel, first-in-class, potential treatment for neurotrophic keratitis.

According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.

The company is rolling out the Biovance 3L ocular tri-layer human amniotic membrane.

When it is not on a mission, the Orbis Flying Eye Hospital MD-10 aircraft often is situated at an airport where the fully accredited teaching facility is put to use as a mobile simulation center to train ophthalmologists from around the world in some of the latest sight-saving techniques.